ABQid

ABQid is a New Mexico-based organization founded in 2014 that operates a twelve-week accelerator program designed for early-stage ventures, particularly in the healthcare and technology sectors. The program emphasizes customer discovery and validation, aiming to equip entrepreneurs with the necessary skills to develop validated business models and prepare for funding. ABQid's mentorship focuses on fostering integrity, accountability, communication, and commitment among participants. By nurturing startups, ABQid seeks to enhance the entrepreneurial ecosystem in Albuquerque and contribute to the local economy. The accelerator program is an opportunity for promising companies to gain guidance and resources as they navigate the challenges of early-stage business development.

TJ Cook

Executive Director, Fund Manager

Past deals in Albuquerque, NM

Peptineo

Seed Round in 2014
Peptineo, LLC is a biotechnology company based in Albuquerque, New Mexico, specializing in drug discovery, delivery, and stabilization technologies. Founded in 2011, the company has developed a diverse pipeline of products, including reformulated aerosolized antibiotics for cystic fibrosis and ventilator-associated pneumonia, a topical antibiotic for MRSA, and a nucleic acid vaccine targeting norovirus. Peptineo also offers a range of antibiotic drugs, aerosolized antimicrobial agents for wound care, vaccines, small interfering RNAs, and injectable biomaterials such as hydrogels and nanoparticles. The company is engaged in research on therapeutic peptides and the reformulation of existing pharmacological compounds, along with hybrid compounds that combine biological proteins with chemical entities. Additionally, Peptineo provides consulting services in biotechnology, pharmaceutical research, and peptide synthesis, alongside outsourced research and development for new biological compounds.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.